Upadacitinib demonstrated significant efficacy in promoting scalp hair regrowth in severe alopecia areata patients, achieving primary endpoints in nearly half of the participants. The phase 3 trials ...

Announces positive data for rosnilimab, a pathogenic T cell depleter, through Week 38 from Phase 2b rheumatoid arthritis trialEnrollment completed for rosnilimab Phase 2 ulcerative colitis trial; ...

Results from the long-term extension of the Phase III TRAILBLAZER-ALZ 2 trial (NCT04437511) showed sustained benefits with ...

Upadacitinib is efficacious for achieving and sustaining endoscopic remission, symptom resolution, and normalization of QOL in long-term UC management.

In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of ...

The ABTECT clinical program included the randomized, double-blind, placebo-controlled phase 3 ABTECT-1 and ABTECT-2 trials.

Abivax dazzled investors and analysts with positive data from a pair of Phase III induction trials assessing obefazimod in adults with moderately to severely active ulcerative colitis. The results ...

Results from the Phase III ABTECT-1 (NCT05507203) and ABTECT-2 (NCT05507216) trials showed that Abivax’s obefazimod demonstrated significant clinical remission in patients with ulcerative colitis.

Abivax has shared positive top-line results from two late-stage studies of its investigational oral miR-124 enhancer in ...

Obefazimod’s strong Phase 3 induction data positions Abivax as leading UC contender with novel mechanism and favorable safety profile. Read why ABVX is a Buy.

The latest announcement is out from Abivax SA Sponsored ADR ( (ABVX) ).

The French biotech is developing a new drug approach in a disease market that’s projected to grow to $30 billion by 2030.